Enclomiphene Hair Loss: DHT, Follicles, and the Evidence

The following blog post is for entertainment and informational purposes only. It is not intended to provide medical advice or diagnosis. Please consult your doctor before making any health-related decisions.

Enclomiphene hair loss does not appear in official prescribing documentation as a listed adverse event, and no controlled trial has established enclomiphene as a direct cause of shedding. The concern is indirect. Enclomiphene is a SERM that raises luteinizing hormone (LH) and stimulates testosterone production, and higher testosterone can convert to dihydrotestosterone (DHT), the androgen primarily responsible for follicle miniaturization in genetically susceptible men. If you are exploring hormone treatment options, understanding enclomiphene and low testosterone first gives you the clinical context for why the DHT question matters.

How low testosterone connects to hair follicles

Low testosterone hair loss is real, but the mechanism is indirect. Testosterone does not damage follicles on its own. The enzyme 5-alpha reductase converts testosterone to DHT in peripheral tissues, including the scalp. DHT then binds to androgen receptors in the dermal papilla of susceptible follicles, gradually shortening the anagen (growth) phase and miniaturizing the follicle over time.

Men with secondary hypogonadism often present with low testosterone alongside suppressed LH and FSH. Chronically low testosterone does not reliably protect hair. What matters is the DHT-to-testosterone ratio, the follicle's genetic sensitivity, and the overall hormonal environment.

Four factors shape how testosterone changes affect hair:

• Genetic susceptibility: Androgen-sensitive scalp zones express more 5-alpha reductase and androgen receptors, making follicles in those areas more reactive to DHT.
• Enzyme activity: Individual 5-alpha reductase activity varies considerably. Some men convert a larger fraction of testosterone to DHT than others.
• Baseline hormone status: Restoring testosterone from a clinically low level is physiologically distinct from elevating already-normal testosterone.
• Concurrent medications: Finasteride and dutasteride block 5-alpha reductase and can reduce DHT significantly, regardless of testosterone level.

These factors explain why the enclomiphene hair loss question does not have a single universal answer.

Does enclomiphene cause hair loss?

When men ask about enclomiphene hair loss specifically, the clinical record is reassuring. Alopecia does not appear in prescribing documentation, and a 2025 systematic review and meta-analysis of randomized controlled trials (Hohl et al., Archives of Endocrinology and Metabolism) found that enclomiphene raised serum testosterone in men with secondary hypogonadism without identifying hair loss as a treatment-emergent event.

Individual responses vary. Some men notice increased shedding when testosterone changes rapidly, especially those with a strong family history of androgenetic alopecia. That shedding, if it occurs, would run through the DHT pathway rather than any direct follicle toxicity from enclomiphene.

Genetics, hormonal imbalance, chronic stress, and nutritional status are each independent causes of hair shedding. Attributing new shedding to enclomiphene alone, without ruling out those factors, is premature.

How does enclomiphene affect hair follicles?

Enclomiphene does not bind to androgen receptors in hair tissue. Its action is upstream. The drug blocks estrogen receptors in the hypothalamus, removes the negative feedback on the pituitary, and prompts increased secretion of LH and FSH. LH then drives testicular testosterone production. Testosterone hair follicles interact only indirectly, through the DHT that forms downstream from that cascade.

This upstream mechanism produces a notably different hormonal pattern compared to testosterone replacement therapy (TRT). TRT delivers exogenous testosterone and suppresses natural LH and FSH. Enclomiphene, as documented by Rodriguez et al. (Expert Opinion on Pharmacotherapy, 2016), preserves the gonadotropin signaling axis while raising testosterone.

Key differences in hormonal pattern between the two approaches:

• Enclomiphene maintains endogenous LH and FSH signaling; TRT suppresses both.
• Enclomiphene produces a more physiological testosterone rise; TRT concentrations vary by formulation and administration route.
• Neither approach fully addresses DHT conversion, and both require monitoring for men with hair-loss risk factors.

Whether enclomiphene's physiological pattern translates to meaningfully lower DHT exposure at the follicle has not been confirmed in trials designed around hair outcomes. The logical argument exists. Supporting trial data does not, yet.

For a look at how the same androgen cascade affects another follicle-dependent tissue, the article on enclomiphene's effects on beard growth covers the testosterone-DHT pathway in a different context.

Does enclomiphene increase DHT levels?

Potentially. Enclomiphene raises total testosterone, and some fraction of that testosterone is converted to DHT through 5-alpha reductase. How much depends on individual enzyme activity, which is genetically determined. Men with high baseline activity may see a proportionally larger DHT rise, and that pathway is the central concern for any enclomiphene hair loss evaluation.

The clinical trials on enclomiphene, including Rodriguez et al. (2016), were designed to measure testosterone, LH, and FSH restoration. DHT-mediated follicle changes were not a primary endpoint. The absence of a hair-loss signal in those trials is meaningful, but it is not proof that DHT does not rise.

In a provider-led protocol, labs typically include total and free testosterone before and after starting treatment. Adding DHT to that panel is a reasonable step for men with a personal or family history of androgenetic alopecia. If DHT rises into a concerning range, a DHT-blocking agent can be added as an adjunct.

Can enclomiphene help with hair growth?

Men researching enclomiphene hair growth should know that enclomiphene is not indicated for hair loss. It also lacks direct randomized-trial evidence as a hair restoration therapy. No large study has used hair density or hair count as a primary endpoint in an enclomiphene trial.

There is a narrower position worth taking seriously. When secondary hypogonadism has produced chronically low testosterone and hair quality has suffered as part of that hormonal disruption, correcting the deficit through a SERM for hair loss purposes could indirectly stabilize the scalp environment. That is restoring normal hormone levels, not a cosmetic boost.

Using enclomiphene in a man with already-normal testosterone, hoping for additional hair growth, is a different and unsupported scenario. Enclomiphene side effects documented in clinical trials did not include hair loss, which is meaningful, but the absence of harm is not evidence of benefit.

For a thorough look at benefits, risks, and mechanism of action, see the full enclomiphene citrate clinical overview.

Can you take enclomiphene and finasteride together?

Yes, some providers do use the two together, since enclomiphene and finasteride target different steps in the same pathway. Enclomiphene raises testosterone by stimulating LH. Finasteride blocks 5-alpha reductase and reduces DHT conversion. Together, they could allow testosterone to normalize while limiting DHT's effect on hair follicles.

Before recommending any combination protocol, a licensed provider typically assesses:

• Current testosterone and DHT levels
• Personal and family history of androgenetic alopecia
• Prior response to, or contraindications for, DHT-blocking therapies
• Awareness of finasteride's adverse sexual effect profile

No large randomized trial has tested this specific combination for hair outcomes. Finasteride does have a well-established independent evidence base: a 2018 systematic review (Lee et al., Journal of Drugs in Dermatology) confirmed efficacy for topical finasteride in androgenetic alopecia.

A 2019 meta-analysis (Lee et al., Acta Dermato-Venereologica) documented the adverse sexual effect risk of oral finasteride. That is a real tradeoff patients must weigh against hair benefits.

For men exploring a topical DHT-blocking option alongside hormone support, the minoxidil-finasteride combination therapy at Valhalla Vitality is one route worth discussing in an intake. Combining two hormonal agents without provider oversight risks overcorrection.

Talk to a provider about your hair and hormone health

Book Your Consultation with a licensed provider who can review your hormone labs, assess your hair-loss pattern, and determine whether enclomiphene, a DHT blocker, or another approach fits your situation.

FAQ

Does enclomiphene cause hair loss?

No clinical trial has confirmed enclomiphene hair loss as a consistent adverse effect, and prescribing documentation does not list alopecia. If shedding occurs while taking enclomiphene, the likely mechanism runs through indirect DHT elevation rather than direct follicle toxicity, and genetic predisposition is a significant factor.

Can enclomiphene help with hair growth?

Enclomiphene is not indicated for hair loss and lacks direct trial evidence as a restoration therapy. Correcting secondary hypogonadism may improve the hormonal environment for hair in men with clinically low testosterone, but a provider must evaluate the underlying cause before drawing any conclusions.

Does enclomiphene increase DHT levels?

Enclomiphene raises testosterone, which can increase DHT through 5-alpha reductase conversion. The degree varies by individual enzyme activity. For men with a family history of androgenetic alopecia, adding DHT to the standard monitoring panel is a reasonable step to discuss with a provider.

Can you take enclomiphene and finasteride together?

Some providers do combine them, as the drugs act at different points in the testosterone-DHT pathway. The combination is mechanistically logical but lacks large-trial validation for hair outcomes. A licensed provider reviews labs and personal history before recommending any multi-drug protocol.

What is a SERM, and why does it matter for hair loss?

A SERM (selective estrogen receptor modulator) blocks estrogen receptors in specific tissues without broad systemic estrogen suppression. Enclomiphene's SERM action in the hypothalamus restores natural LH signaling to raise testosterone, and whether that elevated testosterone then increases DHT is the central question for hair.

Sources

1. Hohl A et al. (2025). Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Archives of Endocrinology and Metabolism. PubMed
2. Rodriguez KM et al. (2016). Enclomiphene citrate for the treatment of secondary male hypogonadism. Expert Opinion on Pharmacotherapy. PubMed
3. Lee SW et al. (2018). A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women. Journal of Drugs in Dermatology. PubMed
4. Lee S et al. (2019). Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis. Acta Dermato-Venereologica. PubMed